Abstract
The N -methyl- d -aspartate (NMDA) receptor is multi-subunit ligand-gated channel which is highly expressed in the mammalian and human central nervous system. Multiple subtypes of the NMDA receptor comprising distinct subunit combinations exist which subserve distinct roles in the brain and spinal cord, which offers new hope to develop, in a rationale fashion, subtype-targetted therapeutic agents. The NR2B subtype represents the most advanced in terms of drug development, with agents currently in clinical trials for chronic pain. Furthermore, memantine a new drug approved for use in Dementias is showing promise as a neuroprotective as well as pro-cognitive agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
